In Vivo Cell Reprogramming
Autoimmune Disorders, Tissue Repair
DiscoveryResearch Stage
Key Facts
Indication
Autoimmune Disorders, Tissue Repair
Phase
Discovery
Status
Research Stage
Company
About Eterna Therapeutics
Eterna Therapeutics is focused on developing transformative mRNA-based cell engineering technologies to create a new generation of cellular medicines. The company's core platform enables precise, in vivo cell reprogramming and gene editing to treat a range of serious diseases. As a publicly traded entity, Eterna is advancing multiple preclinical programs while exploring strategic partnerships to accelerate its pipeline development.
View full company profile